Javier D. L. S.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase I Evaluation of ABBV-525, a MALT1 Inhibitor, in Patients with B-Cell Malignancies
- Phase 3 Study of BGB-11417 plus Zanubrutinib versus Venetoclax plus Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
- Phase II Study of Acalabrutinib and Venetoclax in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line BTKi and BCL2 Inhibitor Therapy
Data & Insights
Has run more than one trial at 100 of 280 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on developing innovative therapeutic approaches for previously untreated patients.
- First-line CLL Treatment Strategies
- Novel Therapeutic Combinations
- Treatment-naive Patient Care
Their research encompasses the evaluation of targeted therapies including BTK inhibitors and novel drug combinations.
Targeted Therapies
Demonstrates expertise in the application of targeted therapeutic agents including ibrutinib, zanubrutinib, and acalabrutinib, focusing on optimizing treatment regimens and investigating combination approaches.
- BTK Inhibitor Optimization
- Combination Therapy Development
- Treatment Customization
Their work involves evaluating fixed-duration versus continuous therapy approaches in hematologic malignancies.
Clinical Outcomes
Focuses on investigating therapeutic efficacy through measurement of progression-free survival and minimal residual disease assessment in blood cancers.
- Response Rate Evaluation
- Treatment Duration Assessment
- Long-term Outcome Analysis
Their research emphasizes the importance of tailored treatment approaches and response monitoring in blood cancer therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.